🔎 Trials Near Me

Utama › Hidradenitis Suppurativa › Michigan

Kajian klinikal Hidradenitis Suppurativa di Michigan

6 kajian untuk Hidradenitis Suppurativa sedang mencari peserta di lokasi di Michigan.

Bandar di Michigan

Teks kajian rasmi (Bahasa Inggeris)

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

  • Oruka Therapeutics Investigative Site, Canton
Mengambil pesertaFasa 2
Umur 18 hingga 79 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07783542

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

  • Investigative Site US061, Ann Arbor
  • Investigative Site US120, Detroit
  • Investigative Site US091, Troy
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06855498

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

  • Oakland Hills Dermatology Pc, Auburn Hills
  • Wayne State University Physician Group Dermatology, Detroit
  • Revival Research Institute, Llc Troy, Troy
Mengambil pesertaFasa 2
Umur 12 hingga 17 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07213973

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

  • Wayne State University, Detroit
  • Hamzavi Dermatology, Fort Gratiot
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mac 2026 · NCT07244263

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

  • University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 24 Jan 2025 · NCT06524635

Battlefield Acupuncture for Pain in Hidradenitis Suppurativa

  • WSUPG Dermatology, Dearborn
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Mei 2023 · NCT04218422

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.